✓ Pago con tarjeta restablecido — compra segura mediante Privacy Shield

Mezcla CagriSema (Cagrilintida 5 mg + Semaglutida 5 mg)

✅ Combinación coformulada de cagrilintida + semaglutida (1:1)
✅ Ambos péptidos en un solo vial (5 mg + 5 mg)
✅ Combinación líder de Novo Nordisk en Fase 3 para obesidad
✅ Efecto de ~20–23% en el peso corporal (REDEFINE-1)
✅ Mecanismos complementarios de amilina + GLP-1

CagriSema es una mezcla coformulada de péptidos.

SKU: N/A Categoría: Etiqueta: , , ,

✓ Revisado médicamente por Morgan Ellis — Investigador farmacéutico · 8 años de experiencia  · Última revisión: mayo de 2026

$50 peptide shipping — dedicated courier applies once per order whenever a Peptides item is in your cart. Product price, this charge, and tax (if any) are shown as separate lines at checkout.

BAC Water
💧 Necesitarás agua BAC para reconstituir este péptido
Agua bacteriostática para inyección — necesaria para mezclar el polvo liofilizado de péptido en una solución inyectable. Un vial de 10 ml reconstituye múltiples viales de péptidos.
Añadir agua BAC (10 ml × 10 Viales, US$50,00) →
¿Ya tienes agua BAC? Omite esto. ¿Necesitas un tamaño de paquete diferente? Ver todos los tamaños →

Respuesta rápida — ¿Qué es CagriSema?

CagriSema es la combinación coformulada de cagrilintida (análogo de amilina de acción prolongada) y semaglutida (agonista de GLP-1 de acción prolongada) en un solo vial liofilizado. Es el programa líder de Novo Nordisk en Fase 3 para la obesidad y produjo reducciones de peso corporal de aproximadamente 20–23% durante 68 semanas en el ensayo REDEFINE-1 — tamaños de efecto comparables a los de un triple agonista retatrutide achieved through the combination of two single-receptor agonists rather than a single multi-agonist molecule. Each vial contains 5 mg cagrilintide + 5 mg semaglutide for clinical studies use only.

Qué obtienes con MedsBase: Pharmaceutical-grade lyophilized peptides · HPLC ≥99% purity (COA on request) · Discreet protective packaging · Worldwide peptide courier · 1,400+ verified opiniones de clientes

📦 Cada pedido está cubierto por nuestra Reshipment Assurance Policy — si tu paquete no llega en 20 días laborables, lo reenviamos.

Especificación Detalle
Composición Cagrilintide 5 mg + Semaglutide 5 mg por vial (proporción de masa 1:1, coformulado)
Péptido total por vial 10 mg de masa total de péptidos (5 mg + 5 mg)
Números CAS de los componentes 1415456-99-3 (cagrilintide) / 910463-68-2 (semaglutide)
Perfil de receptores Familia de receptores de amilina/calcitonina (AMY1/2/3) más Receptor GLP-1 — complementarios mecanísticamente, sin superposición
Forma Polvo liofilizado coformulado (blanco a blanquecino)
Pureza ≥99% (cada componente verificado por HPLC, COA disponible bajo solicitud)
Vida media (por componente) Cagrilintide ~159 horas; Semaglutide ~165 horas — ambos permiten una dosificación subcutánea semanal
Almacenamiento Liofilizado: 2–8 °C (refrigerador) para stock de trabajo; −20 °C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2–8 °C, usar dentro de ~30 días. Proteger de la luz. No congelar-descongelar la solución reconstituida.
Solubilidad Agua bacteriostática (recomendada). Ambos péptidos se reconstituyen simultáneamente desde el mismo vial.

¿Qué es CagriSema?

CagriSema es el nombre en desarrollo de Novo Nordisk para la combinación de proporción fija de dos péptidos de acción prolongada en una única formulación subcutánea: cagrilintida (el análogo de amilina de acción prolongada, código de desarrollo AM833) y semaglutida (el agonista del receptor GLP-1 de acción prolongada comercializado como Ozempic y Wegovy como agente independiente). La combinación es el programa líder de Fase 3 para la obesidad en el pipeline de Novo Nordisk y reportó los resultados del ensayo REDEFINE-1 en 2024–2025: aproximadamente una reducción del 20–23% en el peso corporal durante 68 semanas con la dosis semanal de 2.4 mg + 2.4 mg — efectos que sitúan a CagriSema en el mismo rango que el agonista triple de receptores retatrutide while taking a completely different pharmacological route. The strategic rationale for CagriSema rests on the mecanismos complementarios, no superpuestos of its two component peptides. GLP-1 receptor agonists (semaglutide) act predominantly on hypothalamic arcuate-nucleus POMC neurons (central appetite regulation) and pancreatic beta-cells (glucose-dependent insulin secretion). Amylin/calcitonin receptor agonists (cagrilintide) act predominantly on brainstem area-postrema neurons (per-meal satiety reinforcement) and pancreatic alpha-cells (glucagon suppression). The two mechanisms are mechanistically additive rather than redundant, which is why the combination produces body-weight effects substantially greater than either component alone — demonstrated in the Phase 2 head-to-head data where CagriSema outperformed both cagrilintide monotherapy and semaglutide monotherapy. This pharmaceutical-grade CagriSema co-formulation contains 5 mg de cagrilintide + 5 mg de semaglutide por vial en una proporción de masa 1:1 que coincide con la proporción de dosis fija utilizada en el programa clínico de Fase 3. Ambos componentes están premezclados en el mismo vial liofilizado; la reconstitución con agua bacteriostática produce una solución de trabajo que contiene ambos péptidos simultáneamente. Este enfoque elimina la necesidad de combinar viales separados en el laboratorio. CagriSema no está aprobado by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as of current literature; regulatory submission and review are ongoing. For deeper detail on each component, see our individual Cagrilintida y Semaglutida páginas de productos.

Mechanism of Action — Complementary Dual-Receptor Pharmacology

What makes CagriSema mechanistically distinctive among current metabolic-compounds is that the two component peptides activate entirely different receptor families with non-overlapping central and peripheral mechanisms — achieving multi-axis pharmacology through combination rather than through engineering a single multi-agonist molecule like tirzepatide or retatrutide:

  • GLP-1 receptor arm (semaglutide) — central appetite regulation and glycaemic control — Semaglutide activates the GLP-1 receptor on hypothalamic arcuate-nucleus POMC neurons (suppressing food intake via the central appetite system), pancreatic beta-cells (glucose-dependent insulin secretion), pancreatic alpha-cells (glucagon suppression), and gastric vagal afferents (delayed gastric emptying). This arm provides the canonical incretin pharmacology that semaglutide and other GLP-1 agonists are known for in published studies and approved clinical use.
  • Amylin / calcitonin receptor arm (cagrilintide) — brainstem satiety and per-meal feedback — Cagrilintide activates the amylin receptor heterodimers (AMY1, AMY2, AMY3 — calcitonin receptor + RAMP1/2/3) located densely in the brainstem area postrema, a CNS region that lacks a blood-brain barrier. This produces per-meal satiety reinforcement on a different temporal pattern than GLP-1’s tonic central appetite suppression. The amylin arm also delays gastric emptying via a partly distinct vagal pathway and suppresses postprandial glucagon at pancreatic alpha-cells.
  • Additive vs synergistic effect on body-weight phenotype — The Phase 2 head-to-head data are the cleanest evidence of additive (and possibly synergistic) pharmacology: cagrilintide monotherapy at 2.4 mg weekly produced ~10% body-weight reduction; semaglutide monotherapy at 2.4 mg weekly produced ~15%; the CagriSema combination at 2.4 + 2.4 mg produced ~20–23%. The net effect approaches or exceeds the sum of the individual effects, consistent with the mechanistic prediction that two non-overlapping satiety pathways activated simultaneously produce a stronger anorectic signal than either alone.

Both peptides are acylated with fatty-diacid chains that bind reversibly to circulating serum albumin (cagrilintide uses a C20 chain via γ-Glu-OEG-OEG; semaglutide uses C18 via γ-Glu-AEEA-AEEA). The half-lives are well matched at ~159 hours (cagrilintide) and ~165 hours (semaglutide) — both supporting once-weekly subcutaneous dosing without divergent pharmacokinetics. This pharmacokinetic alignment is one of the design features that makes co-formulation in a single vial practical: the two components can be reconstituted, stored, and dosed together without compromising either’s exposure profile.

Published Evidence

CagriSema co-formulation peptides are used in clinical contexts that investigate:

  • Combination obesity pharmacology — the lead programme: preclinical DIO rodent models, body-composition (DEXA/MRI), food-intake assays, energy-expenditure characterisation; head-to-head against monotherapy arms (cagrilintide alone, semaglutide alone) to dissect the additive vs synergistic question (Enebo et al., Lancet 2021; REDEFINE-1 / REDEFINE-2 Phase 3 results)
  • Type 2 diabetes preclinical studies — glycaemic control, HbA1c surrogates, postprandial glucose dynamics in db/db and high-fat-diet rodent models
  • Comparative multi-agonist studies — head-to-head with single-molecule multi-agonists including Tirzepatida (dual GLP-1/GIP), Retatrutida (triple GLP-1/GIP/glucagon), Mazdutida (dual GLP-1/glucagón), y Survodutida (dual GLP-1/glucagón); la cuestión central es si la farmacología de combinación de dos moléculas tiene alguna ventaja sobre las moléculas mono-multi-agonistas
  • Amylin / GLP-1 axis interaction studies — caracterización de mecanismos no superpuestos, disección de circuitos centrales del apetito en el tronco encefálico frente al hipotálamo, ensayos de ocupación simultánea de receptores
  • Vaciamiento gástrico y fisiología posprandial — tiempo de vaciamiento gástrico bajo tratamiento combinado frente a individual, dinámica de glucosa posprandial, integración del eje hormona-intestino
  • Energy expenditure studies — gasto energético en reposo, cociente de intercambio respiratorio; la combinación CagriSema produce un perfil distinto al de los multi-agonistas que contienen receptores de glucagón (mazdutida, retatrutida) porque ninguno de sus componentes activa el receptor de glucagón
  • Combination-pharmacology design studies — CagriSema como caso de estudio en la formulación de péptidos múltiples en proporción fija, comparación de la farmacocinética de la co-formulación frente a viales separados administrados secuencialmente o conjuntamente.

Para un contexto más amplio, consulte nuestras Cagrilintida y Semaglutida páginas de producto para farmacología a nivel de componente, Retatrutida como la principal alternativa mono-molécula triple-agonista, y Tirzepatida como el comparador dual GLP-1/GIP. Explore el completo catálogo de péptidos para compuestos relacionados.

Configuraciones Disponibles

MedsBase almacena la mezcla CagriSema en una única co-formulación: 5 mg de cagrilintide + 5 mg de semaglutide por vial at the clinical 1:1 mass ratio. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:

Composición del Vial Caso de uso típico Tamaños de paquete
5 mg + 5 mg (cagri + sema) Standard CagriSema studies blend — combination obesity, T2DM, and additive-pharmacology studies at the clinical 1:1 mass ratio 10, 20 o 30 viales

Both components are supplied at ≥99% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. The 5 mg + 5 mg per vial composition supports approximately 2 weeks of clinical-equivalent dosing (2.4 mg + 2.4 mg weekly) per vial — a 10-vial pack covers approximately 20 weeks of studies at the Phase 3 maintenance dose. Compared with buying 10 vials of stand-alone Cagrilintide (5 mg) plus 10 vials of stand-alone Semaglutide (5 mg) separately, the co-formulated blend offers a modest cost saving and the practical convenience of single-vial reconstitution.

Cómo se compara — CagriSema frente a Retatrutida

CagriSema y Retatrutida are the two leading multi-mechanism approaches to maximum-magnitude body-weight effect in current metabolic-peptide studies. They take fundamentally different design approaches: CagriSema combines two single-receptor agonists in a fixed-dose blend, while retatrutide engineers triple-receptor pharmacology into a single molecule. The two reach comparable Phase 2/3 body-weight effect sizes through these distinct routes — the comparison is one of the most-cited in current obesity-pharmacology studies.

Criterio CagriSema Retatrutida
Enfoque de diseño Combinación de dos agonistas de receptor único Molécula única triagonista
Perfil de receptor GLP-1 + Amilina/Calcitonina GLP-1 + GIP + Glucagón
Componentes Cagrilintida + Semaglutida Molécula única (LY3437943)
Desarrollador Novo Nordisk Eli Lilly
Efecto sobre el peso corporal ~20–23% (REDEFINE-1, 68 semanas) ~24% (Fase 2, 48 semanas)
Alineación de vida media ~159 / ~165 horas (bien emparejadas) ~6 días (molécula única, no necesita emparejamiento)
Amplitud del mecanismo Apetito central + saciedad del tronco encefálico + supresión del glucagón Apetito central + lipólisis mediada por GIP + gasto energético impulsado por glucagón
Gasto energético Modest (no glucagon arm) Substantial (glucagon arm)

The pharmacological choice between CagriSema and retatrutide depends on the studies question. For studies interested in maximum body-weight effect with the cleanest receptor-selectivity profile (no off-target GIP or glucagon signalling), CagriSema is the preferred reference. For studies interested in the additional mechanism breadth that glucagon-receptor activation provides (energy expenditure, hepatic lipid mobilisation), retatrutide is the canonical comparator. The combination-vs-single-molecule design question is itself an active area of pharmaceutical studies — both approaches have reached late-stage development, and Phase 3 head-to-head trials are likely to inform the long-term winner.

Almacenamiento y reconstitución

Antes de la reconstitución: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. The lyophilized CagriSema co-formulation is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Both component peptides have closely-matched stability profiles, so storage is governed by whichever peptide degrades first under given conditions — in practice, the two components are remarkably similar. Avoid freeze-thaw cycles on the lyophilized powder. Procedimiento de reconstitución: inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). Because the vial contains 10 mg total peptide mass (5 mg cagri + 5 mg sema), a 2.0 mL reconstitution yields a 5 mg/mL total-peptide working concentration — equivalent to 2.5 mg/mL of each individual component. Approximately 0.96 mL delivers a 2.4 mg + 2.4 mg clinical-equivalent dose. Swirl gently — do ajuste shake — and allow 5–10 minutes for full dissolution (both peptides are acylated and dissolve more slowly than smaller unmodified peptides). A correctly reconstituted solution should be clear and colourless with no visible particles. Después de la reconstitución: store refrigerated at 2–8 °C and use within 30 days for optimal stability of both components. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity and could disproportionately affect either component. Discard any vial showing cloudiness, precipitate, or discolouration.

Preguntas frecuentes

What is CagriSema used for in studies?

CagriSema is used in studies investigating the additive pharmacology of GLP-1 and amylin receptor activation, combination obesity pharmacology, type 2 diabetes preclinical models, comparative head-to-head studies against single-molecule multi-agonists (tirzepatide, retatrutide, mazdutide, survodutide), and combination-pharmacology design questions. It is the lead Phase 3 combination-pharmacology compound in current metabolic-peptide studies from Novo Nordisk. The pharmaceutical-grade CagriSema sold here is ajuste FDA-approved and is supplied strictly for clinical studies use only.

What is in a CagriSema vial?

Cada vial contiene 5 mg of cagrilintide and 5 mg of semaglutide, co-formulated and lyophilized together as a single powder. The 1:1 mass ratio matches the fixed-dose ratio used in the Phase 3 clinical CagriSema programme (2.4 mg + 2.4 mg weekly). Both peptides reconstitute simultaneously when bacteriostatic water is added.

How is CagriSema different from Cagrilintide alone or Semaglutide alone?

CagriSema combines both peptides in one vial. Cagrilintide alone activates only the amylin/calcitonin receptor family and produces approximately 10% body-weight reduction in Phase 2 monotherapy studies. Semaglutide alone activates only the GLP-1 receptor and produces approximately 15% body-weight reduction in Phase 3 monotherapy (STEP trials). The CagriSema combination produces approximately 20–23% — greater than either component alone, because the two mechanisms are non-overlapping (different receptors, different CNS sites, complementary peripheral effects).

How is CagriSema different from Retatrutide?

Both are leading multi-mechanism approaches to body-weight effect, but they take fundamentally different design routes. CagriSema combines two separate single-receptor agonists (cagrilintide + semaglutide) in one vial — combination pharmacology. Retatrutida engineers triple-receptor pharmacology (GLP-1 + GIP + glucagon) into a single molecule. Both reach approximately 20–24% body-weight effect at maintenance dose in Phase 2/3 studies, but through different receptor sets — CagriSema uses GLP-1 + amylin, retatrutide uses GLP-1 + GIP + glucagon.

Why combine the two peptides in a single vial?

Co-formulation has three practical advantages: (1) the half-lives of cagrilintide (~159 h) and semaglutide (~165 h) are well-matched, so a single weekly injection delivers both peptides on the same pharmacokinetic schedule; (2) reconstitution is simpler — one vial, one diluent volume, one withdrawal; (3) fixed-dose-ratio is straightforward because the dose ratio is set at manufacture and cannot drift between separate vial draws. The principal trade-off is that the dose ratio is fixed at 1:1 mass — for studies requiring different ratios, separate vials of cagrilintida y semaglutida may be preferred.

What is the typical CagriSema dose?

Published Phase 3 clinical studies uses 2.4 mg cagrilintide + 2.4 mg semaglutide weekly as the maintenance dose, with a multi-month titration schedule starting at 0.25 mg + 0.25 mg. A vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL of each component (5 mg/mL total peptide mass) — approximately 0.96 mL equals a clinical-equivalent 2.4 mg + 2.4 mg dose.

Is CagriSema FDA approved?

No. CagriSema is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The REDEFINE-1 (obesity) and REDEFINE-2 (T2DM) Phase 3 trials reported positive results in 2024–2025, but regulatory submission and review are ongoing.

How should CagriSema be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade peptide integrity and could disproportionately affect either component. Protect from direct light at all times.

How do I reconstitute CagriSema?

Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 5–10 minutes for full dissolution (both peptides are acylated and dissolve more slowly than smaller unmodified peptides). Do ajuste shake the vial. Both peptides reconstitute simultaneously from the same vial. A correctly reconstituted solution is clear and colourless with no visible particles. For a vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL of each peptide.

¿Qué configuraciones tiene MedsBase en stock?

MedsBase carries the CagriSema co-formulation in a single composition: 5 mg cagrilintide + 5 mg semaglutide per vial (1:1 mass ratio, lyophilized). The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. Each component is verified individually at ≥99% HPLC purity with a certificate of analysis available on request.

Can I buy CagriSema components separately instead?

Yes — MedsBase stocks both component peptides as stand-alone products: Cagrilintida in 5 mg and 10 mg vials, and Semaglutida in 2–50 mg vials. Separate vials are useful if protocols require dose ratios other than the clinical 1:1 mass ratio, or if users want to dose cagrilintide and semaglutide independently. The co-formulated blend offers a small bundle saving and the convenience of single-vial reconstitution for protocols at the 1:1 clinical ratio.

Does CagriSema cause side reported effects?

The side-effect profile of CagriSema in Phase 3 is dominated by gastrointestinal findings shared with both component peptides: nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4–8 weeks of continuous dosing. The combined regimen does not produce qualitatively different side effects from either component alone — the GI-axis tolerability is roughly comparable to semaglutide monotherapy at equivalent doses.

¿Cuál es la vida media de CagriSema?

Ambos péptidos componentes tienen vidas medias plasmáticas muy similares: cagrilintida ~159 horas (~6,5 días) y semaglutida ~165 horas (~7 días). Esta coincidencia es una de las características de diseño que hace práctica la coformulación en un solo vial: ambos péptidos se eliminan de la circulación en el mismo plazo, lo que permite una dosificación semanal sin farmacocinética divergente. El mecanismo de unión a la albúmina (acilación de ácido graso C20/C18) es la base de la vida media prolongada en ambos péptidos.

How long does CagriSema take to show effects in preclinical studies?

Los efectos farmacodinámicos agudos sobre el vaciamiento gástrico, la saciedad por comida y la tolerancia a la glucosa son detectables horas después de la primera dosis. Los efectos sobre el peso corporal en modelos de roedores con obesidad inducida por dieta (DIO) suelen ser estadísticamente significativos después de 1-2 semanas de dosificación semanal y continúan acumulándose hasta las 16-24 semanas. El efecto máximo sobre la composición corporal se desarrolla en 48-68 semanas, coincidiendo con la trayectoria de la Fase 3 del estudio REDEFINE-1.

¿Puedo pedir CagriSema para envío internacional?

Sí. MedsBase envía CagriSema a todo el mundo desde nuestra red dedicada de envío de péptidos. Los pedidos que solo contienen péptidos califican para nuestro servicio de envío de péptidos independiente. Todos los pedidos se envían en embalaje con control de temperatura con seguimiento completo y están cubiertos por nuestro Reshipment Assurance Policy.

Other Peptides for Metabolic, Body-Composition, and Multi-Mechanism Studies

  • Cagrilintida — Análogo de amilina de acción prolongada — el componente de amilina de CagriSema, viales independientes
  • Semaglutida — Agonista de GLP-1 de acción prolongada — el componente de GLP-1 de CagriSema, viales independientes
  • Retatrutida — Agonista triple de GLP-1/GIP/glucagón — alternativa multimolécula única
  • Tirzepatida — Agonista dual de GLP-1/GIP — enfoque alternativo de múltiples mecanismos
  • Mazdutida — Coagonista dual de GLP-1/glucagón — alternativa derivada de oxintomodulina

Lecturas adicionales

📖 Explora el panorama metabólico de la farmacología combinada

Explora toda la catálogo de péptidos, con compuestos relacionados de combinación y múltiples mecanismos, incluyendo Cagrilintida (amilina independiente), Semaglutida (GLP-1 independiente), Retatrutida (agonista triple de molécula única), y Mazdutida (dual GLP-1/glucagón). Guía comparativa: Retatrutida vs Tirzepatida.

Composición

5 mg de cagrilintida + 5 mg de semaglutida

Cantidad

10 Viales, 20 Viales, 30 Viales

Preguntas y respuestas

Haz una pregunta
CagriSema Blend (Cagrilintide 5 mg + Semaglutide 5 mg) Mezcla CagriSema (Cagrilintida 5 mg + Semaglutida 5 mg)
Tu pregunta
* La pregunta es obligatoria
Nombre
* El nombre es obligatorio
No hay preguntas aún